Bio-Path Holdings Inc.

NASDAQ: BPTHHealthcare / Drug Delivery / USA
13.17-0.2500-1.86%Vol 63 8441Y Perf -59.03%
Jun 24th, 2019 16:00
BID13.00 ASK13.18
Open13.24 Previous Close13.42
Pre-Market- After-Trading-
 - -%  - -%
Target Price
20.00 
Analyst Rating
— 0.00
Potencial %
51.86 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)37 
Earnings Rating
Buy
Price Range Ratio 52wk %
16.08 
Earnings Date
16th May 2019

Today's Price Range

12.6413.41

52wk Range

1.6173.52

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Month
-9.63%
3 Months
-38.94%
6 Months
191.74%
1 Year
-59.03%
3 Years
-96.86%
5 Years
-97.95%

Name / TickerPriceChg.Chg.%
BPTH13.17-0.2500-1.86
AAPL198.58-0.2000-0.10
GOOG1 115.52-6.3600-0.57
MSFT137.780.81000.59
XOM76.95-0.7400-0.95
WFC46.27-0.6200-1.32
JNJ143.060.97000.68
FB192.601.46000.76
GE10.28-0.2000-1.91
JPM108.66-0.7800-0.71
Earnings HistoryEstimateReportedSurprise %
Q01 2018--0.17-
Q03 2017-0.20-0.200.00
Q02 2017-0.20-0.30-50.00
Q01 2017-0.20-0.1050.00
Q04 2016--0.10-
Q03 2016-0.20-0.200.00
Q02 2016-0.02-0.020.00
Q01 2016-0.02-0.020.00
Earnings Per EndEstimateRevision %Trend
12/2017 QR-0.200.00-
12/2017 FY-0.800.00-
3/2018 QR-0.200.00-
12/2018 FY-0.900.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume63 844
Shares Outstanding (in ths.)2 831
Trades Count245
Dollar Volume665 085
Avg. Volume2 218 733
Avg. Weekly Volume61 120
Avg. Monthly Volume139 475
Avg. Quarterly Volume418 027
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Rating--Strong Buy
1.00

Bio-Path Holdings Inc.

Bio-Path Holdings Inc is a United States based clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and in combination with decitabine. The other drug candidates of the company are BP1002 and BP1003.

CEO: Peter H. Nielsen

Teplephone: +1 832 742-1357

Address: 4710 Bellaire Boulevard, Bellaire 77401, TX, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

63%38%

Bearish Bullish

46%54%

Bearish Bullish

45%55%

News